Visible Genetics, Inc.
This article was originally published in The Gray Sheet
Executive SummaryPrivate placement of 1.9 mil. shares with U.S. and European institutional investors raises $28.7 mil. A portion of the funds will be used to gear up U.S. marketing and manufacturing efforts for the TruGene HIV-I genotyping kit, an FDA regulatory submission for which is anticipated in the first half of 2000 (1"The Gray Sheet" Dec. 6, p. 14). The proceeds will be directed toward new product development and for general working capital, the Toronto firm says
You may also be interested in...
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.